New Zealand markets open in 8 hours 1 minute

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
40.16+1.42 (+3.67%)
At close: 04:00PM EST
40.07 -0.09 (-0.22%)
Pre-market: 07:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous close38.74
Bid39.82 x 800
Ask40.06 x 900
Day's range39.63 - 40.27
52-week range30.10 - 49.07
Avg. volume371,828
Market cap26.266B
Beta (5Y monthly)0.69
PE ratio (TTM)60.90
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry

    Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.

  • Motley Fool

    Genmab A/S (GMAB) Q2 2021 Earnings Call Transcript

    Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Hello, and welcome to the Genmab conference call to discuss the Company's financial results for the first half of 2021.

  • Zacks

    Is a Surprise Coming for Genmab (GMAB) This Earnings Season?

    Genmab (GMAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.